The disclosure relates to implantable medical devices and, more particularly, to implantable medical devices that occlude appendages.
The left atrial appendage (LAA) is a pouch-like extension of the left atrium of the heart. In some patients, blood clots form in the LAA. These blood clots may dislodge and enter the bloodstream, migrate through the anatomy, and block a vessel in the brain or heart, for example. A blocked vessel may cause cardiac arrhythmia, e.g., atrial fibrillation, which may lead to ischemic stroke.
Implanted medical devices are available for insertion into the ostium of the LAA to occlude the LAA and thus block blood clots from entering into the systemic circulation. In general, these devices are delivered to the LAA through a catheter system that enters the venous circulation, e.g., the inferior vena cava, and approaches the left atrium through the atrial septum between the right and left side of the heart, e.g., via a previously created hole in the atrial septum created using transseptal crossing techniques. The delivery catheter is guided through the septum toward the ostium of the LAA. After acquisition and insertion into the LAA, the implanted medical device is deployed so that it remains in the appendage. Once positioned, the implanted medical device is released by the catheter, and the catheter system is removed.
In general, this disclosure describes techniques for occluding the ostium of the left atrial appendage (LAA) of a heart. In some cases, a device that includes compression springs is positioned at the ostium of the LAA. A cover disposed about the device occludes the LAA and prevents blood clots from entering the blood stream. The device may be configured to ensure that any size and geometry of ostium of an LAA is occluded.
In one embodiment, this disclosure is directed to a device an implantable medical device for insertion in a left atrial appendage of a patient comprising a center hub having a longitudinal axis and a first side and a second side, a plurality of compression springs, each of the plurality of compression springs extending radially from the center hub, and a cover disposed about the compression springs and engaged to center hub on both the first side and the second side.
In another embodiment, this disclosure is directed to a method of implanting a medical device for insertion into a left atrial appendage. The method comprises providing an implantable medical device that comprises a center hub having a longitudinal axis and a first side and a second side, a plurality of compression springs, each of the plurality of compression springs extending radially from the center hub, and a cover disposed about the compression springs and engaged to center hub on both the first side and the second side. The method further includes collapsing the device within a deliver catheter and deploying the device at a deployment site by removing the device from the delivery catheter and allowing the compression springs to expand.
The details of one or more aspects of the disclosure are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims.
This disclosure describes techniques for occluding the ostium of an appendage, e.g., the left atrial appendage (LAA) of a heart. In some examples, the techniques may be effective in preventing cardiac arrhythmia, e.g., atrial fibrillation, by blocking blood clots formed in the LAA from entering the bloodstream. A vessel blocked by a blood clot may cause cardiac arrhythmia, e.g., atrial fibrillation, which may lead to ischemic stroke.
Left atrial appendage ostia have various sizes and geometries. As such, many existing LAA occluding devices are available in numerous sizes in order to accommodate the specific size of each patient's ostium. Currently, in some cases, prior to implantation of an LAA occluding device, a clinician estimates the size of a patient's ostium, e.g., using an average of measurements taken from several trans-esophageal echocardiogram images. Once the size of the patient's ostium is estimated, the clinician selects an occluding device having dimensions that will fit that patient's ostium. Hence, many differently-sized occluding devices must be manufactured, stocked, and available to the clinician in order to accommodate the variation in ostium sizes.
Although existing occluding devices are available in numerous sizes to accommodate variations in ostium size, the aforementioned existing occluding devices may not accommodate variations in ostium geometries between patients. That is, because of the irregularity of the shape of the ostium, many existing occluding devices may not conform entirely to the shape of a patient's ostium. As such, undesirable gaps may exist between the ostium wall and existing occluding devices.
In accordance with some example techniques of this disclosure, an implantable medical device is disclosed that can accommodate variations in both the size and geometry of the ostium of the LAA. In addition, after deployment the device may be easily recaptured and redeployed until the device properly seals off the LAA and prevents blood clots from entering the bloodstream.
As shown and described in more detail below with respect to
As seen in the example depicted in
In some examples, compression springs 12 are made of a biocompatible metal. In one example configuration, compression springs 12 are made of a shape-memory material such as a nickel-titanium alloy, e.g., nitinol. In another example, configuration, compression springs 12 are made of stainless spring steel.
As indicated above and in accordance with this disclosure, device 10 is designed to sealingly engage various sizes and geometries of ostia. In order to accommodate the various sizes and geometries of ostia, device 10 may have a diameter in the range of about 26 millimeter (mm) to about 36 mm. In one example configuration, device 10 may have a diameter of about 34 mm.
In addition, in one example configuration, device 10 should apply a force of about 200 grams against an ostium wall to provide a sufficient compression fit that will prevent device 10 from becoming dislodged. The spring constant of a compression spring will depend on the number of springs 12 in device 10. For example, device 10 of
In addition, it should be noted that device 10 of
In some examples, each of springs 12 of device 10 has substantially the same spring constant. In other examples, one or more of springs 12 has a spring constant that is different from the spring constants of the other springs 12.
Each of springs 12 extend through center hub 16 of device 10. Upon exiting hub 16, one end of each of springs 12 are wrapped around hub 16 to form coil 18. Springs 12 may be secured by welding them to hub 16. In another example, springs 12 may be secured to the hub via a crimp ring, which is then welded to hub 16.
In order to occlude the LAA and thus block blood clots from entering the bloodstream, device 10 includes cover 14. Cover 14 attaches at hub 16 on both sides of device 10. Cover 14 is disposed about and fully encloses springs 12.
Cover 14 is made of a material that provides the desired permeability for an intended use. In some examples, cover 14 may block the passage of blood clots, but is permeable to blood flow therethrough, e.g., such as a filter. Alternatively, cover 14 can be of a material impermeable to blood flow. Cover 14 may be fabricated from any suitable biocompatible material such as, but not limited to, expanded polytetrafluoroethylene or ePFTE, (e.g., Gortex®), polyester, (e.g., Dacron®), PTFE (e.g., Teflon®), silicone, urethane, metal fibers, and other biocompatible polymers.
In some examples, at least a portion of one or more of springs 12 and/or cover 14 is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the framework, which is adapted to be released at the site of the framework's implantation or areas adjacent thereto.
A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.
It may be desirable to provide aspects of device 10 with the ability to safely biodegrade over time. Thus, in some examples, springs 12 and/or cover 14 is constructed from biodegradable materials that are also biocompatible. A biodegradable material is a material that will undergo breakdown or decomposition into harmless compounds as part of a normal biological process.
In one example configuration, device 10 may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some examples, at least a portion of one or more of springs 12 or hub 16 is at least partially radiopaque.
In other example configurations, as shown and described in more detail below with respect to
It should be noted that in some example configurations, each of springs 12 are not spaced substantially equally apart from one another (not depicted). Rather, it may be desirable for two springs 12, for example, to be closer to one another than other pairs of springs 12.
Device 10 further includes connector 40. In one example, connector 40 is threaded to releaseably couple device 10 to a delivery catheter. Connector 40 allows device 10 to be deployed and recaptured and redeployed, if necessary. Of course, a threaded connector is only one specific example of connector. Other example connectors are considered within the scope of this disclosure. Device 10 is tethered to the delivery catheter via a deployment wire (not depicted). In some examples, the deployment wire has a screw on one end to engage connector 40.
As seen in
It should be noted that in some examples there may be more than two sets of springs 12. In addition, in one example configuration, one set of compression springs may have more or fewer springs than another set of springs 12. For example, set 34 of
In the particular example depicted in
It should be noted that in some examples there may be more than two sets of springs 12. In addition, in one example configuration, one set of compression springs may have more or fewer springs than another set of device 10. For example, set 34 of
To load device 10, a clinician, for example, collapses device 10 within a delivery catheter. Compression springs 12 of device 10 are bent proximally within the delivery catheter during delivery. In a partially deployed state, a portion of compression springs 12 remains within the delivery catheter during delivery. When device 10 is properly positioned and fully deployed, device 10 is untethered from the deployment wire. It should be noted that device 10 may also be preloaded into a delivery catheter by the device manufacturer.
During recapture by the delivery catheter, compression springs 12 are pulled proximally into the delivery catheter. Compression springs 12 of device 10 are bent distally as device 10 is recaptured by the delivery catheter.
Various aspects of the disclosure have been described. These and other aspects are within the scope of the following claims.
This application claims priority from U.S. Application No. 61/589,989, filed on Jan. 24, 2012, the entire contents of which is hereby incorporated by reference.
Number | Date | Country | |
---|---|---|---|
61589989 | Jan 2012 | US |